Venezia, Italy
Venezia, Italy

Time filter

Source Type

Diffractive optical element (6) of the holographic type, which diffractively generates, when illuminated by a predetermined first electromagnetic field (DOB) having non-zero orbital angular momentum, a second electromagnetic field (IOB) forming a first image substantially lacking noise, indicative of information encoded by the diffractive optical element (6). In addition, the diffractive optical element (6) diffractively generates, when illuminated by a third electromagnetic field, a fourth electromagnetic field forming a noisy image. The first and the third electromagnetic field having different topological charges and/or different spatial distributions of phase singularities.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.3-1 | Award Amount: 13.58M | Year: 2013

SUN (Sustainable Nanotechnologies) is the first project addressing the entire lifecycle of nanotechnologies to ensure holistic nanosafety evaluation and incorporate the results into tools and guidelines for sustainable manufacturing, easily accessible by industries, regulators and other stakeholders. The project will incorporate scientific findings from over 30 European projects, national and international research programmes and transatlantic co-operations to develop (i) methods and tools to predict nanomaterials exposure and effects on humans and ecosystems, (ii) implementable processes to reduce hazard and exposure to nanomaterials in different lifecycle stages, (iii) innovative technological solutions for risk management in industrial settings, and (iv) guidance on best practices for securing both nano-manufacturing processes and nanomaterials ultimate fate, including development of approaches for safe disposal and recycling. In summary, SUN stands for an integrated approach for the long-term sustainability of nanotechnologies through the development of safe processes for production, use and end-of-life processing of nanomaterials and products, as well as methods reducing both adverse effects and exposure to acceptable levels.


Grant
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: NMP.2012.1.2-3 | Award Amount: 1.77M | Year: 2012

Nanomedicine, the application of nanotechnology to health, is a fast-growing field with a large potential for improving diagnostics and therapeutic solutions in many diseases. The EuroNanoMed II (ENM II) consortium, with 20 partners from 17 countries and regions, aims to foster the competitiveness of European nanomedicine actors through the support of translational research projects enhancing transnational and multidisciplinary collaborations between academia, clinical/public health communities and industry. ENM II will be a follow-up of the ERA-NET EuroNanoMed I (ENM I), which launched three joint transnational calls for proposals in three years. The increasing number of submitted proposals in the successive ENM I joint calls and their quality show the need amongst the nanomedicine scientific community for such a targeted initiative. ENM II will be built on the basis of the ENM I accomplishments, and will continue to support transnational innovative RTD projects in nanomedicine through the launch of yearly joint calls for proposals. In addition, ENM II aims to extend the cooperation among its partners through the development of other activities: (i) foster the participation of young European researchers to ENM II activities; ii) develop a strategic agenda for ENM II in close cooperation to the ETP Nanomedicine; iii) create more interactions within the European nanomedicine community and improve communication on nanomedicine to the public; iv) frame and address regulatory, safety and ethical issues associated with nanomedicine; v) monitor the results of the ENM I & ENM II funded research projects and the activities of the ENM II network; and, vi) develop a long-term cooperation framework for European nanomedicine research. Therefore, through joint funding of translational nanomedicine projects and its other activities, ENM II will contribute to enhance coordination of research and resources in this field, thereby shaping the European Research Area in nanomedicine.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2012.1.3-3 | Award Amount: 49.52M | Year: 2013

The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answers needed by regulators and legislators on EHS by linking them to a scientific evaluation of data and test methods. Based on questions and requirements supplied by regulators and legislators, NANoREG will: (i) provide answers and solutions from existing data, complemented with new knowledge, (ii) Provide a tool box of relevant instruments for risk assessment, characterisation, toxicity testing and exposure measurements of MNMs, (iii) develop, for the long term, new testing strategies adapted to innovation requirements, (iv) Establish a close collaboration among authorities, industry and science leading to efficient and practically applicable risk management approaches for MNMs and products containing MNMs. The interdisciplinary approach involving the three main stakeholders (Regulation, Industry and Science) will significantly contribute to reducing the risks from MNMs in industrial and consumer products. NANoREG starts by analysing existing knowledge (from WPMN-, FP- and other projects). This is combined with a synthesis of the needs of the authorities and new knowledge covering the identified gaps, used to fill the validated NANoREG tool box and data base, conform with ECHAs IUCLID DB structure. To answer regulatory questions and needs NANoREG will set up the liaisons with the regulation and legislation authorities in the NANoREG partner countries, establish and intensify the liaisons with selected industries and new enterprises, and develop liaisons to global standardisation and regulation institutions in countries like USA, Canada, Australia, Japan, and Russia.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP-2010-1.3-1 | Award Amount: 13.15M | Year: 2011

The growing development, production and use of engineered nanomaterials and associated products will increase exposure of both humans and ecosystems to these new materials. However, current knowledge is still incomplete and established test methods are as yet inappropriate to reliably assess the extent of exposure and risk of materials at the nano-scale. There is an urgent need to develop methods to overcome the current limitations of existing hazard and risk assessment schemes and to generate the body of reference data needed as the basis for regulative requirements and for measures to safeguard production, application and the disposal of nanomaterials. The proposed project will mobilize the critical mass of international scientific knowledge and technical expertise required to address these questions. Current analytical and toxicity test methods and models will be put to test and subjected to rigorous intercalibration and validation. Where necessary, methods and test materials will be modified, adapted and validated, and new reliable reference methods developed, in cooperation with international standardisation bodies and the concerned industry, to support both pre and co-normative activities and to make the applicability of existing RA and LCA schemes to ENPs more reliable. The feasibility of validated measurement, characterization and test methods will be assessed by selected case studies to help the significant improvement of the performance of existing exposure monitoring systems as well as the development of new risk management and reduction strategies.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2011.1.2-2 | Award Amount: 10.76M | Year: 2012

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improvement of classical therapies and it would also make a high number of new therapies feasible. To make this happen, the final objective of Trans-INT is to design nanocarriers specifically adapted to deal with the gastrointestinal ecosystem and use them for the development of new oral nanomedicines for diseases with high socioeconomic impact (i.e. metabolic diseases, pain medication). The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering (multifunctional nanocarriers: high payload, drug protection, efficient drug transport, controlled release) and pharmaceutical technology criteria (scalable technology and stability). The project will start with nanocarrier platforms on which the partners have IPR and freedom to operate: nanocapsules, nanoparticles, micelles made of combinations of lipids, polypeptides and polysaccharides, continue with the optimization and redefinition of selected nanocarriers. It is expected to end with (i) at least one oral nanocarrier prototype with a comprehensive GLP-tox package, which could be applied for the delivery of a high number of peptide molecules, (ii) at least one nanomedicine fulfilling target product profile criteria, with a comprehensive preclinical evaluation package, (iii) substantial integrative knowledge on the feasibility and potential of oral nanocarriers and nanopharmaceuticals. TRANS-INT is expected to have a great impact no only from the new therapies/patients perspective but also from the innovation and EU industrial development perspective.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: AAT.2013.4-4. | Award Amount: 5.59M | Year: 2013

CORSAIR project is a wide investigation concerning the capabilities of Cold Spray Technology for maintenance and repair of aeronautic frames and components. Today, deep and systematic investigation in Cold Spray is required to better understand the capabilities and fully validate the technology in aeronautics. In this scenario, the activities planned in CORSAIR project are (1) Explore the real capabilities of Cold Spray in several practical examples of aeronautic repair applications; real components to be repaired will be selected by aeronautic companies and cold spray repair protocols defined during the project. A condensed list of the parts and repairs considered during the project includes the Repairs of New Parts: castings and machined parts exhibiting different kind of defects; and the Restoration of Serviced Parts and components. The Base and deposition Materials are Light Alloys such as Al, Ti and Mg alloys. Homogeneous Repair (repair where the deposited material is the same of the base material) and Heterogeneous Repair (repair where the deposited material is different with respect to the base material) will be considered. (2) deep investigate the coating and repair characteristics (mechanical, microstructural, thermal and chemical properties) in order to finely tune and define where Cold Spray could be further applied for maintenance and repair in aeronautics. (3) deep investigate the effect and the characteristics of feedstock materials required for deposition (4) to give the required reliability to the coating deposition and repair processes to validate the technology for aeronautic industry. (5) To surpass the actual technological limitations of line-in-sight Cold Spray deposition process developing new nozzles for out-of-view surfaces. (6) To develop a New Industrial Portable Cold Spray Unit to extend the capabilities of in situ maintenance and repair applications. CORSARI has been previously submitted to AAT-2012-RTD-1 obtaining a score of 13/15.


Grant
Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: NMP.2011.1.3-3 | Award Amount: 907.90K | Year: 2012

The background, concept and objectives of ITS-NANO are straight forward. The volume of information on hazard characterisation of ENM is increasing fast. In parallel with the scientific development, regulation orientated initiatives are also taking place to identify needs. The ITS-NANO concept is 1: Gather targeted all scientific evidence, by literature search and communication with leading scientists. 2: Develop an initial assessment (document) of the available knowledge and the gaps, focussed on identifying knowledge level as how to develop an intelligent approach to grouping ENMs based their properties and their subsequent biological impacts in order to intelligently design next-generation nanosafety evaluation and risk assessment strategies. 3: Assemble stakeholders for presenting the initial assessment, having a dialog on how this relates to their aims/needs and how to make a consent driven strategy forward that ensures communication. 4: Revise the initial assessment document with the input from the stakeholder sent around for commenting, presenting the next draft for a smaller group for final commenting. 5: Publish it.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ENV-NMP.2011.2.2-5 | Award Amount: 2.83M | Year: 2011

The main objective is to develop a novel atmospheric plasma technique for surface cleaning and coating deposition as well as two innovative coatings: a self-diagnostic protective coating and a coating provided with identification marker. The project aims at integrating the new plasma cleaning/deposition technique and the new coatings in a full-life protocol spanning surface cleaning and pre-treatment, deposition of protective and identification coatings, and complete removal of coatings. The plasma technique is proposed for surface cleaning and coating removal as alternative or complementary to the other non-contact techniques such as laser. This technique is characterized by no thermal heating, selectivity, chemical reduction of oxides, applicability on all substrates and competitive costs. The self-diagnostic coatings provide a long-lasting solution with an added value of easy and instant diagnostic of coating functionality through a nano-technological approach, reducing monitoring costs and time with no impact on tourist accessibility. The identification marker coating allows using nanotechnologies to obtain a transparent authenticity proof and cataloguing label. The compatibility of the new materials with the substrates is guaranteed intrinsically by their integration in the full-life protocol because it ensures its complete reversibility. The protocol is applicable on all substrate materials principally as preventing conservation, in the project its validation is proposed on metal substrates (silver and bronze) and on mural paintings, limestone and sandstone. The project also aims at implementing a demonstrator of the entire full-life protocol, which will be used for training cultural operators in organised events and fairs. An added value is also the strong participation of SMEs as conservation operators and as technological companies, which ensures the possibility of scaling up and placing the new products on the market.


Patent
Veneto Nanotech S.C.P.A. | Date: 2013-11-06

A method for treating a fibre substrate, including the steps of feeding a substrate along a feed path, stretching the substrate longitudinally to reduce the thickness of the substrate to a value less than 1 mm and then treating the substrate with plasma at atmospheric pressure at a treatment station (T) located.

Loading Veneto Nanotech Scpa collaborators
Loading Veneto Nanotech Scpa collaborators